Join to access to all OVN content. Join for Free
Season 1, Episode 13: Leadership Through Vulnerability with Gwen Binder

Season 1, Episode 13: Leadership Through Vulnerability with Gwen Binder


Share This Article


In today's episode our host Michael Pietrack sits down with Gwendolyn Binder, President of Science and Technologies at Cabaletta Bio, shares her insights on leadership. She discusses how she became an accidental leader and the importance of focusing on advancing the ball for patients rather than personal recognition. Binder emphasizes the need for leaders to embrace uncertainty and have an entrepreneurial attitude. She also highlights the importance of unleashing the potential of others and aligning a unified vision. Binder discusses the role of culture in leadership and the need for leaders to be vulnerable and create a teamwork culture. She provides tips for hiring and emphasizes the importance of no-regret hires. "Instead of trying to think how can I climb the ladder, it's how can I be of most use continually?" Binder also addresses the challenges and advice for female leaders. Tune in to hear it all!

Takeaways

🏀Focus on advancing the ball for patients rather than personal recognition.

🤗Embrace uncertainty and have an entrepreneurial attitude.

💹Unleash the potential of others and align a unified vision.

➡⬅Create a teamwork culture by being vulnerable and open.

☑Make no-regret hires by assessing cultural fit and soft skills.

🚺Acknowledge and address the challenges faced by female leaders. 

Watch on YouTube

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Leveraging existing data to contextualize phase II clinical trial findings in oncology
OVN Avatar E.M. Ray, L.A. Carey, K.E. Reeder-Hayes

Leveraging existing data to contextualize phase II clinical trial findings in oncology

Podcast
Patient Education for Next-Generation Sequencing to Guide Cancer Therapy
OVN Avatar The Oncology Nursing Podcast

Patient Education for Next-Generation Sequencing to Guide Cancer Therapy

Article
Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration
OVN Avatar Kelvin Chan, Seungree Nam, Bill Evans, Claire de Oliveira Alexandra Chambers, Scott Gavura, Jeffrey Hoch, Rebecca E Mercer, Wei Fang Dai, Jaclyn Beca, Mina Tadrous, Wanrudee Isaranuwatchai

Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration

Article
Value assessment of oncology drugs using a weighted criterion-based approach
OVN Avatar Doreen A. Ezeife MD, Francois Dionne PhD, Aline Fusco Fares MD, Ellen Laura Rose Cusano MD, Rouhi Fazelzad BSc, MISt, Wenzie Ng BSc, MPharm, RPh, Don Husereau BSc Pharm, MSc, Farzad Ali BPharm, MSc, Christina Sit MSc, Barry Stein B.Com BCL, LLB, Jennifer

Value assessment of oncology drugs using a weighted criterion-based approach

Article
Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects
OVN Avatar Haiqing Isaac Dai, Yulia Vugmeyster, Naveen Mangal

Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects

Article
Proportion of Patients in Phase I Oncology Trials Receiving Treatments That Are Ultimately Approved
OVN Avatar Sean X Zhang, MSc , Dean Fergusson, PhD , Jonathan Kimmelman, PhD

Proportion of Patients in Phase I Oncology Trials Receiving Treatments That Are Ultimately Approved

Explore OVN